No Data
No Data
Guangdong Lifestrong Pharmacy to Raise Stake in Wannianqing Pharma to Nearly 93%
Yue Jiangxi Wannianqing Cement (301111.SZ) plans to increase investment in its controlling subsidiary Jiangxi Wannianqing Cement Pharmaceutical by 22.8 million yuan.
Yue Jiangxi Wannianqing Cement (301111.SZ) issued an announcement that its controlling subsidiary, Guangdong Jiangxi Wannianqing Pharmaceutical Co., Ltd. (the following...)
Guangdong Wannianqing: 2024 Annual Results Forecast
Are Guangdong Lifestrong Pharmacy Co., Ltd.'s (SZSE:301111) Mixed Financials Driving The Negative Sentiment?
Yue Jiangxi Wannianqing Cement (301111.SZ): Currently, there is no production or sales of Pharmaceuticals for the treatment of monkeypox.
On January 13, Gelonghui reported that Jiangxi Wannianqing Cement (301111.SZ) stated on the investor interaction platform that the company currently does not produce or sell any Pharmaceuticals for the treatment of monkeypox.
Yue Jiangxi Wannianqing (301111.SZ): Sangqi hypoglycemic tablets are proposed to be selected for centralized bulk purchasing.
On January 2, Gelonghui reported that Guangdong Wannianqing Pharmaceutical Co., Ltd. (301111.SZ) recently participated in the centralized procurement work of the National Chinese Patent Medicine Procurement Alliance. According to the "Proposed Selected Results of the Centralized Bulk Procurement of the National Chinese Patent Medicine Procurement Alliance" issued by the Hubei Medical Insurance Service Platform on December 30, 2024, the company's product, Shensi Jiangtang Tablets, is proposed to be selected for this centralized bulk procurement. This proposed selected product, Shensi Jiangtang Tablets, is the company's exclusive formulation and is included in the National Medical Insurance and National Basic Drug List. The sales revenue of the company's Shensi Jiangtang Tablets for the 2023 fiscal year was 0.113 billion yuan, accounting for the company's 202...